Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT1 | P04628 | 5/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.38 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
| ▸ | CLK3 | P49761 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 7/20 | 0.37 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5767627 | 0.84 | MAP2K4 (0.43) | WNT1DYRK1AMAP2K4LRRK2KDM4E | |
| SCHEMBL5873067 | 0.83 | MKNK1 (0.43) | MAP2K4LRRK2KDM4EALDH1A1PIM1 | |
| SCHEMBL5769525 | 0.83 | PIM1 (0.41) | WNT1DYRK1ACLK2CLK3MAP2K4 | |
| SCHEMBL6505794 | 0.82 | DYRK1A (0.56) | WNT1DYRK1A | |
| SCHEMBL5873058 | 0.82 | DYRK1A (0.52) | WNT1DYRK1APIM1 | |
| SCHEMBL5873213 | 0.81 | DYRK1A (0.40) | WNT1DYRK1AKDM4EALDH1A1MAPT | |
| SCHEMBL5872978 | 0.81 | CYP2C9 (0.42) | PIM1 | |
| SCHEMBL5872886 | 0.81 | NAMPT (0.39) | WNT1DYRK1AMAP2K4KDM4EALDH1A1 | |
| SCHEMBL5872868 | 0.80 | CYP2C9 (0.40) | ALDH1A1PIM1 | |
| SCHEMBL5872947 | 0.80 | HCRTR1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984652-B2 | Gyrase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-10 | — | — | US | disclosed |
| US-20050250823-A1 | Gyrase inhibitors | YAGER KRAIG | 2005-11-10 | — | — | US | disclosed |
| US-20050054697-A1 | Gyrase inhibitors | PFIZER INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054697-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | WNT1 3712/4885DYRK1A 1836/4885CLK2 2359/4885 |
| US-20050250823-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | WNT1 3712/4885DYRK1A 1836/4885CLK2 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.